Sanofi’s fourth-quarter financials have failed to impress and while the firm touted an upcoming chronic obstructive pulmonary disease (COPD) readout for its mega blockbuster Dupixent as a future growth driver, some analysts remained unconvinced.
The French group’s Q4 sales came in 2% shy of analyst consensus estimates at €10.73bn, a rise of 7.3% in...








